

<b>Reference:</b>	FOI.12165.23
<b>Subject:</b>	Prescribed treatments
<b>Date of Request:</b>	10 July 2023

**Requested:**

In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Orladeyo (berotralstat)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant)
- Icatibant – any brand except Firazyr

**Response:**

Hywel Dda University Health Board (UHB) can confirm that the only treatments dispensed from the list provided, within the requested timeframe, were Berinert (Human C1-esterase inhibitor) and Firazyr (Icatibant).

The UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018 (DPA) / UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR defines personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.